Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. Focus on "The mTOR/p70 S6K1 pathway regulates vascular smooth muscle differentiation"

American Journal of Physiology - Cell Physiology

Volumn 286, Issue 3 55-3, 2004, Pages

  Lucchesi, Pamela A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACTILE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; MYOSIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; RAPAMYCIN; RETINOBLASTOMA PROTEIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

BLOOD VESSEL OCCLUSION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DRUG ELUTING STENT; EDITORIAL; HUMAN; MAMMAL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

MAMMALIA;

EID: 1442325395     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00526.2003     Document Type: Editorial

References (12)

1. Braun-Dullaeus RC, Mann MJ, and Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98: 82-89, 1998.
2. Díez-Juan A and Andrés V. Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 92: 402-410, 2003.
3. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, and Badimon JJ. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99: 2164-2170, 1999.
4. Li JM and Brooks G. Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Eur Heart J 20: 406-420, 1999.
5. Martin KA, Rzucidlo EM, Merenick BL, Fingar DC, Brown DJ, Wagner RJ, and Powell RJ. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 286: C507-C517, 2004.
6. Marx SO, Jayaraman T, Go LO, and Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76: 412-417, 1995.
7. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, and Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346: 1773-1780, 2002.
8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, and Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323, 2003.
9. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, and Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98: 2277-2283, 1996.
10. Reusch HP, Zimmermann S, Schaefer M, Paul M, and Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 276: 33630-33637, 2001.
11. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, and Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103: 192-195, 2001.
12. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, and Rabbani LE. Role for p27(Kip1) in vascular smooth muscle cell migration. Circulation 103: 2967-2972, 2001.